市場調査レポート
商品コード
1122146

希少疾患遺伝子検査市場規模、シェア&動向分析レポート:疾患タイプ別(神経、CVD)、専門分野別(分子、生化学)、技術別(NGS、PCRベース)、エンドユーザー別、セグメント別予測、2022年~2030年

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease Type (Neurological, CVDs), By Specialty (Molecular, Biochemical), By Technology (NGS, PCR-based), By End Use, And Segment Forecasts, 2022 - 2030

出版日: | 発行: Grand View Research | ページ情報: 英文 150 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
希少疾患遺伝子検査市場規模、シェア&動向分析レポート:疾患タイプ別(神経、CVD)、専門分野別(分子、生化学)、技術別(NGS、PCRベース)、エンドユーザー別、セグメント別予測、2022年~2030年
出版日: 2022年08月08日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

希少疾患遺伝子検査市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界の希少疾患遺伝子検査市場規模は、予測期間中に13.94%のCAGRを記録し、2030年までに25億2000万米ドルに達すると予測されています。希少疾患と戦うための効果的な規制計画は、この産業の主要な推進要因の1つです。さらに、関連する疾患に関するデータや関連情報を提供するレジストリの相当数の存在が、過去数年の収益拡大に寄与しています。希少疾患や超希少疾患に関する認識を高めるための継続的な会議が、診断キットやサービスの採用を後押しすると予想されます。例えば、英国、ドイツ、オランダ、ポーランドなどに拠点を置くエルゴメド社やPSRオーファンエキスパート社は、この分野の認知度向上を目的としたさまざまな活動に参加しています。

さらに、カナダ希少疾患機関(CORD)は、医療政策の合理化のための強力なプラットフォームと、疾患を持つ患者さんの管理に特化した医療システムを提供しています。この機関は、臨床医、研究者、政府、診断業界と協力し、国内のすべての希少疾患の研究開発、診断、治療、サービスの提供を進めています。米国国立衛生研究所(NIH)によると、約3,000万人の米国人が7,000以上の既知の希少疾患のいずれかに罹患していることが確認されています。認知度の向上に伴い、疾患検査を受ける患者数は今後増加すると予想されます。米国では、「希少疾病の日」を制定し、認知度を高めることでこの分野の発展を促進しています。

また、希少疾患臨床研究ネットワーク(RDCRN)の存在は、疾患の診断と治療に取り組む患者、研究者、臨床医を含む23の活発なコンソーシアムや研究グループからなるNIH資金による研究ネットワークで、業界にプラスの影響を与えると予想されます。COVID-19の大流行の中、未診断の希少疾患を持つ患者は、健康上の大きな課題に直面しています。米国の研究者グループが2021年1月に発表した研究によると、希少・未診断疾患(RUD)患者や家族に影響を与える深刻な課題を軽減できるアプローチの開発が急務であるとされています。この課題には、診断や予後の不確実性、医療の複雑さなどが含まれ、健康状態の悪化につながることがあります。

パンデミックによって生じた課題に対応するため、患者支援団体や専門家集団がこれらの課題に積極的に関与しています。例えば、希少染色体支援団体(Unique)、英国ゲノム医学会、英国遺伝同盟などは、疾患を持つ患者の支援、擁護、情報提供などに積極的に取り組んでいます。いくつかの希少疾患は分類されていないままです。慈善団体SWAN U.K.は、英国では毎年約6,000人の子どもが遺伝的疾患を抱えて生まれていると推定していますが、同機関によると、これらの疾患は極めて稀であり、名前をつけることができません。そのため、エビデンスに基づく治療のための適切な診断や予後予測ができないのが現状です。現在、英国では遺伝子検査を受けた子どもの約50%が確定診断を受けられないと言われています。

学習障害のある子どもの約50%、先天性疾患のある子どもの約60%が、障害の原因を特定するための確定診断を受けていません。さらに、診断や遺伝子検査に関する患者や家族の認識不足が、業界の成長をさらに妨げています。北米は、希少疾患の発生率の高さ、多数の登録、この分野の相当数の研究開発施設の存在、診断への大規模な投資により、2021年の業界を支配しました。アジア太平洋地域は、疾病管理に注力している多数の組織の存在により、予測期間中に最も速いCAGRを記録すると予想されます。

希少疾患遺伝子検査市場レポートハイライト

2021年には免疫学的疾患分野が大きなシェアを占めました。多発性硬化症の症例の増加は、このセグメントの主要な重点分野の1つであるため、成長を促進します。

技術別では、2022年から2030年にかけてNGSセグメントが最も速いCAGRを記録すると予想されます。

これは、がん、神経疾患、CVD、小児疾患、精神疾患、その他の希少疾患の検査にNGSベースの遺伝子パネルが利用可能になり、採用されるためである

分子遺伝学的検査専門セグメントは、研究&臨床環境での高い採用により、2021年に最大の収益シェアを占めました。CLIA免除の分子遺伝学的検査の増加も有利な成長機会を提供している

研究機関やCROで実施される遺伝子検査の数が多いことから、研究機関・CROエンドユーザー部門が2021年の業界をリードした

目次

第1章 調査手法

  • 調査の仮定
  • 調査手法
  • 情報調達
  • 情報またはデータ分析
  • 市場の策定と検証
  • 市場モデル
    • 市場調査、疾患別
    • 技術別の市場調査
    • 市場調査、専門分野別
    • 最終用途別の市場調査
    • 地域分析
    • 企業の市場シェア分析

第2章 エグゼクティブサマリー

  • 市場概要

第3章 市場変数、動向、および範囲

  • 市場セグメンテーション
  • 希少疾患遺伝子検査市場:業界ピラミッド分析
    • 親市場の見通し
    • 関連/補助的な市場の見通し
  • テクノロジーの浸透と成長の見通しマッピング、2021年
  • 要因別のSWOT分析(政治と法律、経済、技術)
  • ポーターのファイブフォース分析
  • COVID-19影響分析
    • COVID-19中の希少疾患遺伝子検査ソリューション

第4章 業界の見通し

  • 市場力学
    • 市場促進要因分析
      • 希少疾患の患者登録の拡大
      • 疾患診断におけるシーケンシングコストの低下と技術の進歩
      • 希少疾患診断におけるプログラムと新製品開発の開始
    • 市場制約分析
      • 効果的な診断フレームワークの欠如
      • 遺伝子検査とデータ管理に関連する技術的課題
    • 市場機会分析
      • 希少疾患の診断に対する政府および規制当局の支援
    • 市場課題分析
      • まれな病気の状態についての限られた認識
  • 規制の枠組み
    • 米国
    • 欧州
    • 中国
    • 日本
  • 主要取引と戦略的提携分析
    • 新製品の発売
    • 合併と買収
    • パートナーシップ
  • 希少疾患遺伝子検査市場:企業の市場シェア分析

第5章 疾患別ビジネス分析

  • 希少疾患遺伝子検査市場:病型変動分析
  • 神経疾患
  • 免疫疾患
  • 血液疾患
  • 内分泌・代謝疾患
  • 筋骨格系疾患
  • 心血管疾患(Cvd)
  • 皮膚科疾患
  • その他の希少疾患

第6章 テクノロジービジネス分析

  • 希少疾患遺伝子検査市場:技術変動分析
  • 次世代シーケンシング(NGS)
    • 全エクソームシーケンシング(WES)
    • 全ゲノムシーケンシング(WGS)
  • アレイ技術
  • PCRベースの検査
  • FISH
  • サンガーシーケンシング
  • 核型分析

第7章 専門ビジネス分析

  • 分子遺伝学的検査
  • 染色体遺伝子検査
  • 生化学的遺伝子検査

第8章 最終用途のビジネス分析

  • 調査とCRO
  • 診断検査室
  • 病院と診療所

第9章 地域ビジネス分析

  • 希少疾患遺伝子検査市場:地域動向変動分析
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • スペイン
    • フランス
    • イタリア
    • オランダ
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • 韓国
    • シンガポール
    • オーストラリア
    • 東南アジア
  • ラテンアメリカ
    • ブラジル
  • 中東とアフリカ
    • 南アフリカ

第10章 企業プロファイル

  • 戦略的枠組み
  • 会社の参加者の分類
  • 企業プロファイル
    • CENTOGENE NV
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • INVITAE CORPORATION
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • 3 BILLION, INC.
      • 会社概要
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • ARUP LABORATORIES
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • EUROFINS SCIENTIFIC
      • 会社概要
      • EUROFINS Genoma Group Srl a socio unico
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • STRAND LIFE SCIENCES
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • QUEST DIAGNOSTICS INCORPORATED
      • 会社概要
      • Blueprint Genetics Oy
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • PERKINELMER GENOMICS
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
    • REALM IDX, INC.
      • 会社概要
      • アンブリー遺伝学
      • 会社概要
      • 財務実績
      • 財務実績:AMBRY GENETICS
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • PSOMAGEN INC.(MACROGEN, INC.)
      • 会社概要
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • BAYLOR GENETICS
      • 会社概要
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • COLOR GENOMICS, INC.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • HEALTH NETWORK LABORATORIES
      • 会社概要
      • 結合組織遺伝子検査
      • 会社概要
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • PREVENTION GENETICS
      • 会社概要
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • PROGENITY, INC.
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • COOPERSURGICAL, INC.
      • 会社概要
      • ジェネシスジェネティクス
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • FULGENT GENETICS INC,
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • MYRIAD GENETICS, INC.
      • 会社概要
      • 株式会社カウンシル
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 会社概要
      • シーケノム
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • OPKO HEALTH, INC.
      • 会社概要
      • バイオリファレンス研究所
      • 会社概要
      • GENEDX
      • 会社概要
      • 財務実績
      • 製品のベンチマーク
      • 戦略的イニシアチブ
    • ARTEMIS DNA
      • 会社概要
      • 製品のベンチマーク
図表

List of Tables

  • Table 1 Inheritance pattern of rare diseases
  • Table 2 Distribution of registries by EU countries
  • Table 3 Rare disease policy and regulatory frameworks in EU
  • Table 4 North America rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 5 North America rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 6 North America NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 8 North America rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 9 U.S. rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 10 U.S. rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 13 U.S. rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Canada rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 15 Canada rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 16 Canada NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 17 Canada rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 18 Canada rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Europe rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 20 Europe rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 21 Europe NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 23 Europe rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Germany rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Germany rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 27 Germany rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 28 Germany rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 29 U.K. rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 30 U.K. rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 31 U.K. NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 32 U.K. rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 33 U.K. rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Spain rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 35 Spain rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 36 Spain NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 37 Spain rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 38 Spain rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 39 France rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 40 France rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 41 France NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 42 France rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 43 France rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Italy rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 45 Italy rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 46 Italy NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 47 Italy rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 48 Italy rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Netherlands rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 50 Netherlands rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 51 Netherlands NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 52 Netherlands rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 53 Netherlands rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Japan rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 60 Japan rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 61 Japan NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 62 Japan rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 63 Japan rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 64 China rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 65 China rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 66 China NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 67 China rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 68 China rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 69 India rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 70 India rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 71 India NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 72 India rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 73 India rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Korea rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 75 South Korea rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 76 South Korea NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 77 South Korea rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 78 South Korea rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 79 Singapore rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 80 Singapore rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 81 Singapore NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 82 Singapore rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 83 Singapore rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Australia rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 85 Australia rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 86 Australia NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 87 Australia rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 88 Australia rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 89 South East Asia rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 90 South East Asia rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 91 South East Asia NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 92 South East Asia rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 93 South East Asia rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 94 Latin America rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 95 Latin America rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 96 Latin America NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 97 Latin America rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 98 Latin America rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 99 Brazil rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 100 Brazil rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 101 Brazil NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 102 Brazil rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 103 Brazil rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 104 MEA rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 105 MEA rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 106 MEA NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 107 MEA rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 108 MEA rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 109 South Africa rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 110 South Africa rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 111 South Africa NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 112 South Africa rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 113 South Africa rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain Based Sizing and Forecasting
  • Fig. 6 QFD Modelling for Market Share Assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Rare diseases by inheritance pattern
  • Fig. 9 Definition of rare diseases by region
  • Fig. 10 Prevalence of Multiple sclerosis
  • Fig. 11 Prevalence rate of selected rare diseases in 2021
  • Fig. 12 Distribution of research projects for rare diseases
  • Fig. 13 Penetration of technologies in the rare disease diagnostics market
  • Fig. 14 QFD modeling for market share assessment for specialty scope, by type
  • Fig. 15 Penetration by end-use settings
  • Fig. 16 Regional analysis of rare disease genetic testing market
  • Fig. 17 QFD modeling for company market share assessment
  • Fig. 18 QFD modeling workflow for company market share assessment
  • Fig. 19 Rare disease genetic testing market snapshot, 2021 (USD Million)
  • Fig. 21 Ancillary market analysis
  • Fig. 22 Penetration and growth prospect mapping for specialty, 2021
  • Fig. 23 SWOT analysis, by a factor (Political & legal, economic, and technological)
  • Fig. 24 Porter's Five Forces Analysis
  • Fig. 25 Rare disease genetic testing market driver impact
  • Fig. 26 Distribution of registries by affiliation in EU
  • Fig. 27 Illumina's sequencing cost per MB
  • Fig. 28 Rare disease genetic testing market restraint impact
  • Fig. 29 Challenges in rare disease diagnosis
  • Fig. 30 Company market share analysis
  • Fig. 31 Rare disease genetic testing market: Disease type outlook and key takeaways
  • Fig. 32 Rare disease genetic testing market: Disease type movement analysis
  • Fig. 33 Global genetic testing market for rare neurology diseases, 2018 - 2030 (USD Million)
  • Fig. 34 Global genetic testing market for rare immunologic disorders, 2018 - 2030 (USD Million)
  • Fig. 35 Global genetic testing market for rare hematology diseases, 2018 - 2030 (USD Million)
  • Fig. 36 Global genetic testing market for rare endocrine & metabolism diseases, 2018 - 2030 (USD Million)
  • Fig. 37 Global genetic testing market for rare cancer forms, 2018 - 2030 (USD Million)
  • Fig. 38 Global genetic testing market for rare musculoskeletal disorders, 2018 - 2030 (USD Million)
  • Fig. 39 Global genetic testing market for rare cardiovascular disorders, 2018 - 2030 (USD Million)
  • Fig. 40 Global genetic testing market for rare dermatology diseases, 2018 - 2030 (USD Million)
  • Fig. 41 Global genetic testing market for other rare diseases, 2018 - 2030 (USD Million)
  • Fig. 42 Rare disease genetic testing market: Technology outlook and key takeaways
  • Fig. 43 Rare disease genetic testing market: Technology movement analysis
  • Fig. 44 DNA sequencing cost per genome
  • Fig. 45 DNA sequencing cost per genome
  • Fig. 46 Global NGS-based Rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 47 Comparison of growth in genetic testing units for exome & targeted exome, custom genes, large (>500 gene) panels
  • Fig. 48 Global WES-based rare disease genetic testing market 2018 - 2030 (USD Million)
  • Fig. 49 Global WGS-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 50 Global array specialty-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 51 Global PCR-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 52 Global FISH-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 53 Global sanger sequencing-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 54 Global karyotyping-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 55 Rare disease genetic testing market: Specialty outlook and key takeaways
  • Fig. 56 Rare disease genetic testing market: Specialty movement analysis
  • Fig. 57 DNA sequencing cost per Mb
  • Fig. 58 Global molecular genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 59 Global chromosomal genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 60 Global biochemical genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 61 Rare disease genetic testing market: End-use outlook and key takeaways
  • Fig. 62 Rare disease genetic testing market: End-use movement analysis
  • Fig. 63 Global research laboratories & CROs-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 64 Global diagnostic laboratories-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 65 Global hospitals & clinics-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 66 Rare disease genetic testing market: Regional outlook and key takeaways
  • Fig. 67 Rare disease genetic testing market: Regional movement analysis
  • Fig. 68 North America
  • Fig. 69 North America rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 U.S.
  • Fig. 71 U.S. rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Canada
  • Fig. 73 Canada rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Europe
  • Fig. 75 Europe rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Germany
  • Fig. 77 Germany rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 U.K.
  • Fig. 79 U.K. rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Spain
  • Fig. 81 Spain rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 France
  • Fig. 83 France rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Italy
  • Fig. 85 Italy rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 The Netherlands
  • Fig. 87 The Netherlands rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Asia-Pacific
  • Fig. 89 Asia-Pacific rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Japan
  • Fig. 91 Japan rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 China
  • Fig. 93 China rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 India
  • Fig. 95 India rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 South Korea
  • Fig. 97 South Korea rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Singapore
  • Fig. 99 Singapore rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Australia
  • Fig. 101 Australia rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 South East Asia
  • Fig. 103 South East Asia rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Latin America
  • Fig. 105 Latin America rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 106 Brazil
  • Fig. 107 Brazil rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 108 Middle East & Africa
  • Fig. 109 MEA rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 110 South Africa
  • Fig. 111 South Africa rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Strategy framework
  • Fig. 113 Company participant categorization
目次
Product Code: GVR-4-68038-695-0

Rare Disease Genetic Testing Market Growth & Trends:

The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to a new report by Grand View Research, Inc. Effective regulatory plans to combat rare disease is one of the key drivers of the industry. Furthermore, the presence of a substantial number of registries that provide data and relevant information about related diseases has aided in revenue growth over the past years. Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services. For instance, Ergomed and PSR Orphan Experts, with their offices in the U.K., Germany, the Netherlands, Poland, and other countries, participate in various activities that are aimed at raising awareness in this area.

Moreover, the Canadian Organization for Rare Disorders (CORD) offers a strong platform to streamline health policy and a healthcare system that is dedicated to the management of patients with disorders. The agency works with clinicians, researchers, governments, and the diagnostic industry to advance R&D, diagnosis, treatment, and service availability for all rare conditions in the country. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. The number of patients undergoing disease testing is expected to increase in the coming years with growing awareness. The U.S. celebrates Rare Disease Day and promotes developments in this area by raising awareness.

In addition, the presence of the Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active consortia or research groups that includes patients, researchers, and clinicians who are focused on the diagnosis & treatment of disorders is anticipated to positively impact the industry. Amidst the COVID-19 pandemic, patients with undiagnosed and rare diseases have been facing significant health challenges. According to a study published in January 2021 by a group of researchers from the U.S., there is an urgent need for the development of approaches that can reduce the serious challenges affecting Rare & Undiagnosed diseases (RUD) patients and families. The challenges include diagnostic and/or prognostic uncertainty coupled with medical complexity leading to poor health outcomes.

In response to the challenges created by the pandemic, patient support groups and professional societies are actively involved in addressing these challenges. For instance, the Rare Chromosome Support Group (Unique), the British Society for Genomic Medicine, and Genetic Alliance U.K. are actively involved in supporting, advocating, and providing information to patients with diseases. Several rare conditions remain unclassified. The charity SWAN U.K. estimated that around 6,000 children are born each year with genetic conditions in the U.K. As per the agency, the conditions are extremely rare and cannot be named. Thus, there is a lack of proper diagnosis and prognosis for evidence-based treatment. At present, around 50% of the children who undergo genetic testing in the U.K. would not receive a confirmed diagnosis.

Around 50% of the children with learning disabilities and approximately 60% of children with congenital conditions do not receive a definitive diagnosis to identify the cause of their disabilities. Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth. North America dominated the industry in 2021 due to the high incidence of rare diseases, a large number of registries, the presence of substantial numbers of R&D facilities in this area, and extensive investments in diagnosis. Asia Pacific is expected to register the fastest CAGR during the forecast years owing to the presence of a substantial number of organizations that are focusing on disease management.

Rare Disease Genetic Testing Market Report Highlights:

  • The immunological disorders segment held a significant revue share in 2021. A rise in the cases of multiple sclerosis drives the growth as is one of the key focus areas in this segment
  • Based on technology, the NGS segment is expected to register the fastest CAGR from 2022 to 2030
  • This is due to the availability & adoption of NGS-based gene panels for cancer, neurologic disease, CVD, pediatric conditions, psychiatric disorders, and another rare disease testing
  • The molecular genetic tests specialty segment held the largest revenue share in 2021 due to the high adoption in research & clinical settings. A rise in CLIA-waived molecular genetic tests also offers lucrative growth opportunities
  • The research laboratories & CROs end-user segment led the industry in 2021 owing to a large number of genetic tests conducted in research laboratories and CROs

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research Assumptions
  • 1.2 Research Methodology
  • 1.3 Information Procurement
  • 1.4 Information or Data Analysis
  • 1.5 Market Formulation & Validation
  • 1.6 Market Model
    • 1.6.1 Market Study, By Disease
    • 1.6.2 Market Study, By Technology
    • 1.6.3 Market Study, By Specialty
    • 1.6.4 Market Study, By End Use
    • 1.6.5 Regional Analysis
    • 1.6.6 Company Market Share Analysis

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation
  • 3.2 Rare Disease Genetic Testing Market: Industry Pyramid Analysis
    • 3.2.1 Parent Market Outlook
    • 3.2.2 Related/Ancillary Market Outlook
  • 3.3 Penetration and Growth Prospect Mapping for Technology, 2021
  • 3.4 SWOT analysis, by a factor (Political & legal, economic, and technological)
  • 3.5 Porter's Five Forces Analysis
  • 3.6 COVID-19 Impact Analysis
    • 3.6.1 Rare Disease Genetic Testing Solutions During Covid-19

Chapter 4 Industry Outlook

  • 4.1 Market Dynamics
    • 4.1.1 Market Driver Analysis
      • 4.1.1.1 Expanding patient registry for rare disease
      • 4.1.1.2 Declining Sequencing Cost & Technological Advancements In Disease Diagnosis
      • 4.1.1.3 Launch Of Programs & New Product Development In Rare Disease diagnosis
    • 4.1.2 Market Restraint Analysis
      • 4.1.2.1 Absence Of Effective Diagnosis Framework
      • 4.1.2.2 Technical Challenges Associated With Genetic Tests & Data Management
    • 4.1.3 Market Opportunity Analysis
      • 4.1.3.1 Government & Regulatory Support For Rare Disease Diagnosis
    • 4.1.4 Market Challenge Analysis
      • 4.1.4.1 Limited Awareness about The Rare Disease Conditions
  • 4.2 Regulatory Framework
    • 4.2.1 U.S.
    • 4.2.2 Europe
    • 4.2.3 China
    • 4.2.4 Japan
  • 4.3 Major Deals And Strategic Alliances Analysis
    • 4.3.1 New Product Launch
    • 4.3.2 Mergers And Acquisitions
    • 4.3.3 Partnerships
  • 4.4 Rare Disease Genetic Testing Market: Company Market Share Analysis

Chapter 5 Disease Type Business Analysis

  • 5.1 Rare Disease Genetic Testing Market: Disease Type Movement Analysis
  • 5.2 Neurological Diseases
    • 5.2.1 Global Genetic Testing Market For Rare Neurological Diseases, 2018 - 2030 (USD Million)
  • 5.3 Immunological Disorders
    • 5.3.1 Global Genetic Testing Market For Rare Immunological Disorders, 2018 - 2030 (USD Million)
  • 5.4 Hematology Diseases
    • 5.4.1 Global Genetic Testing Market For Rare Hematology Diseases, 2018 - 2030 (USD Million)
  • 5.5 Endocrine & Metabolism Diseases
    • 5.5.1 Global Genetic Testing Market For Rare Endocrine & Metabolism Diseases, 2018 - 2030 (USD Million)
  • 5.6 Cancer
    • 5.6.1 Global Genetic Testing Market For Rare Cancer Forms, 2018 - 2030 (USD Million)
  • 5.7 Musculoskeletal Disorders
    • 5.7.1 Global Genetic Testing Market For Rare Musculoskeletal Disorders, 2018 - 2030 (USD Million)
  • 5.8 Cardiovascular Disorders (Cvd)
    • 5.8.1 Global Genetic Testing Market For Rare Cardiovascular Disorders, 2018 - 2030 (USD Million)
  • 5.9 Dermatology Diseases
    • 5.9.1 Global Genetic Testing Market For Rare Dermatology Diseases, 2018 - 2030 (USD Million)
  • 5.10 Other Rare Diseases
    • 5.10.1 Global Genetic Testing Market For Other Rare Diseases, 2018 - 2030 (USD Million)

Chapter 6 Technology Business Analysis

  • 6.1 Rare Disease Genetic Testing Market: Technology Movement Analysis
  • 6.2 Next Generation Sequencing (NGS)
    • 6.2.1 Global NGS-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
    • 6.2.2 Whole Exome Sequencing (WES)
      • 6.2.2.1 Global WES-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
    • 6.2.3 Whole Genome Sequencing (WGS)
      • 6.2.3.1 Global WGS-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.3 Array Technology
    • 6.3.1 Global Array Technology-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.4 Pcr-Based Testing
    • 6.4.1 Global Pcr-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.5 Fish
    • 6.5.1 Global Fish-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.6 Sanger Sequencing
    • 6.6.1 Global Sanger Sequencing-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.7 Karyotyping
    • 6.7.1 Global Karyotyping-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)

Chapter 7 Speciality Business Analysis

  • 7.1 Molecular Genetic Tests
    • 7.1.1 Global Molecular Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)
  • 7.2 Chromosomal Genetic Tests
    • 7.2.1 Global Chromosomal Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)
  • 7.3 Biochemical Genetic Tests
    • 7.3.1 Global Biochemical Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)

Chapter 8 End-Use Business Analysis

  • 8.1 Research Laboratories & CROs
    • 8.1.1 Global Research Laboratories & CROs-based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Global Diagnostic Laboratories-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 8.3 Hospitals & Clinics
    • 8.3.1 Global Hospitals & Clinics-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)

Chapter 9 Regional Business Analysis

  • 9.1 Rare Diseases Genetic Testing Market: Regional Movement Analysis
  • 9.2 North America
    • 9.2.1 North America Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.3 U.K.
      • 9.3.3.1 U.K. Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.4 Spain
      • 9.3.4.1 Spain Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.5 France
      • 9.3.5.1 France Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.6 Italy
      • 9.3.6.1 Italy Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.7 The Netherlands
      • 9.3.7.1 The Netherlands Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.4 India
      • 9.4.4.1 India Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.5 South Korea
      • 9.4.5.1 South Korea Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.6 Singapore
      • 9.4.6.1 Singapore Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.7 Australia
      • 9.4.7.1 Australia Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.8 South East Asia
      • 9.4.8.1 South East Asia Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.6 Middle East And Africa
    • 9.6.1 Middle-East And Africa Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Strategy Framework
  • 10.2 Company Participant categorization
  • 10.3 Company Profiles
    • 10.3.1 CENTOGENE N.V.
      • 10.3.1.1 Company overview
      • 10.3.1.2 Financial performance
      • 10.3.1.3 Product benchmarking
      • 10.3.1.4 Strategic initiatives
    • 10.3.2 INVITAE CORPORATION
      • 10.3.2.1 Company overview
      • 10.3.2.2 Financial Performance
      • 10.3.2.3 Product benchmarking
      • 10.3.2.4 Strategic initiatives
    • 10.3.3 3 BILLION, INC.
      • 10.3.3.1 Company overview
      • 10.3.3.2 Product benchmarking
      • 10.3.3.3 Strategic initiatives
    • 10.3.4 ARUP LABORATORIES
      • 10.3.4.1 Company overview
      • 10.3.4.2 Financial Performance
      • 10.3.4.3 Product benchmarking
      • 10.3.4.4 Strategic initiatives
    • 10.3.5 EUROFINS SCIENTIFIC
      • 10.3.5.1 Company overview
      • 10.3.5.2 EUROFINS Genoma Group Srl a socio unico
      • 10.3.5.2.1 Company Overview
      • 10.3.5.3 Financial Performance
      • 10.3.5.4 Product benchmarking
      • 10.3.5.5 Strategic initiatives
    • 10.3.6 STRAND LIFE SCIENCES
      • 10.3.6.1 Company overview
      • 10.3.6.2 Financial Performance
      • 10.3.6.3 Product benchmarking
      • 10.3.6.4 Strategic initiatives
    • 10.3.7 QUEST DIAGNOSTICS INCORPORATED
      • 10.3.7.1 Company overview
      • 10.3.7.2 Blueprint Genetics Oy
      • 10.3.7.2.1 Company Overview
      • 10.3.7.3 Financial Performance
      • 10.3.7.4 Product benchmarking
      • 10.3.7.5 Strategic initiatives
    • 10.3.8 PERKINELMER GENOMICS
      • 10.3.8.1 Company overview
      • 10.3.8.2 Financial Performance
      • 10.3.8.3 Product benchmarking
    • 10.3.9 REALM IDX, INC.
      • 10.3.9.1 Company overview
      • 10.3.9.2 Ambry Genetics
      • 10.3.9.2.1 Company Overview
      • 10.3.9.3 Financial Performance
      • 10.3.9.3.1 Financial Performance: AMBRY GENETICS
      • 10.3.9.4 Product benchmarking
      • 10.3.9.5 Strategic initiatives
    • 10.3.10 PSOMAGEN INC. (MACROGEN, INC.)
      • 10.3.10.1 Company overview
      • 10.3.10.2 Product benchmarking
      • 10.3.10.3 Strategic initiatives
    • 10.3.11 BAYLOR GENETICS
      • 10.3.11.1 Company overview
      • 10.3.11.2 Product benchmarking
      • 10.3.11.3 Strategic initiatives
    • 10.3.12 COLOR GENOMICS, INC.
      • 10.3.12.1 Company overview
      • 10.3.12.2 Financial performance
      • 10.3.12.3 Product benchmarking
      • 10.3.12.4 Strategic initiatives
    • 10.3.13 HEALTH NETWORK LABORATORIES
      • 10.3.13.1 Company overview
      • 10.3.13.2 Connective Tissue Gene Tests
      • 10.3.13.2.1 Company overview
      • 10.3.13.3 Product benchmarking
      • 10.3.13.4 Strategic initiatives
    • 10.3.14 PREVENTION GENETICS
      • 10.3.14.1 Company overview
      • 10.3.14.2 Product benchmarking
      • 10.3.14.3 Strategic initiatives
    • 10.3.15 PROGENITY, INC.
      • 10.3.15.1 Company overview
      • 10.3.15.2 Financial performance
      • 10.3.15.3 Product benchmarking
      • 10.3.15.4 Strategic initiatives
    • 10.3.16 COOPERSURGICAL, INC.
      • 10.3.16.1 Company overview
      • 10.3.16.2 Genesis Genetics
      • 10.3.16.2.1 Company overview
      • 10.3.16.3 Financial performance
      • 10.3.16.4 Product benchmarking
      • 10.3.16.5 Strategic initiatives
    • 10.3.17 FULGENT GENETICS INC,
      • 10.3.17.1 Company overview
      • 10.3.17.2 Financial Performance
      • 10.3.17.3 Product benchmarking
      • 10.3.17.4 Strategic initiatives
    • 10.3.18 MYRIAD GENETICS, INC.
      • 10.3.18.1 Company overview
      • 10.3.18.2 Counsyl, Inc.
      • 10.3.18.2.1 Company overview
      • 10.3.18.3 Financial Performance
      • 10.3.18.4 Product benchmarking
      • 10.3.18.5 Strategic initiatives
    • 10.3.19 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 10.3.19.1 Company overview
      • 10.3.19.2 Sequenom
      • 10.3.19.2.1 Company overview
      • 10.3.19.3 Financial Performance
      • 10.3.19.4 Product benchmarking
      • 10.3.19.5 Strategic initiatives
    • 10.3.20 OPKO HEALTH, INC.
      • 10.3.20.1 Company overview
      • 10.3.20.2 Bio-Reference Laboratories
      • 10.3.20.2.1 Company overview
      • 10.3.20.2.2 GENEDX
      • 10.3.20.2.2.1 Company overview
      • 10.3.20.3 Financial Performance
      • 10.3.20.4 Product benchmarking
      • 10.3.20.5 Strategic initiatives
    • 10.3.21 ARTEMIS DNA
      • 10.3.21.1 Company overview
      • 10.3.21.2 Product benchmarking